{"id":11054,"date":"2020-10-20T15:08:05","date_gmt":"2020-10-20T09:38:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11054"},"modified":"2021-07-24T12:58:08","modified_gmt":"2021-07-24T07:28:08","slug":"pharma-news-for-roche-prestige-covid-19","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19","title":{"rendered":"Venclexta full approval; PBP1510 Orphan Status; Roche\/ Genesis collab; Immunomodulators for COVID-19"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69deaa4ef1bbf\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69deaa4ef1bbf\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\/#Full_FDA_Approval_for_Venclexta_Combinations_for_Acute_Myeloid_Leukemia\" >Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia\u00a0\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\/#Positive_EMA_Opinion_on_Orphan_status_for_Prestige_Biopharmas_PBP1510_for_Pancreatic_Cancer\" >Positive EMA Opinion on Orphan status for Prestige Biopharma\u2019s PBP1510 for Pancreatic Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\/#NIH_begins_a_large_clinical_trial_to_investigate_Immunomodulators_for_COVID-19\" >NIH begins a large clinical trial to investigate Immunomodulators for COVID-19<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\/#Genesis_Therapeutics_Roche_together_on_the_road_to_AI-driven_drug_discovery\" >Genesis Therapeutics, Roche together on the road to AI-driven drug discovery<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Full_FDA_Approval_for_Venclexta_Combinations_for_Acute_Myeloid_Leukemia\"><\/span><strong>Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia\u00a0\u00a0<\/strong><gwmw style=\"display:none;\"><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\" target=\"_blank\" rel=\"noreferrer noopener\">acute myeloid leukemia (AML)<\/a> in adults 75 years or older who are unfit for intensive induction chemotherapies.&nbsp;<\/p>\n\n\n\n<p>The approval is based on the results of clinical trial Phase lll VIALE-A &amp; VIALE-C. VIALE-A trial demonstrated a significant reduction in the risk of death and higher rates of complete remissions upon administration of Venclexta in a combination of azacytidine as compared to azacytidine alone. The drug has already bagged the accelerated FDA approval in this setting, and with the recent results, the drug has managed to get full approval.&nbsp;<\/p>\n\n\n\n<p>Venclexta is a joint venture between AbbVie and Roche. Both the goliaths jointly commercialize it in the US, however, outside the US, AbbVie handles the marketing of the drug.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Positive_EMA_Opinion_on_Orphan_status_for_Prestige_Biopharmas_PBP1510_for_Pancreatic_Cancer\"><\/span><strong>Positive EMA Opinion on Orphan status for Prestige Biopharma\u2019s PBP1510 for Pancreatic Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prestige BioPharma has announced that it has secured Orphan Drug Designation (ODD) status for its first-in-class anti-PAUF monoclonal antibody, PBP1510 <a href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-pancreatic-cancer-market-size\/\">Pancreatic cancer<\/a> by the European Medicines Agency (EMA).&nbsp;<\/p>\n\n\n\n<p>The drug has already received the Orphan drug designation from the USFDA earlier this year in June, from the Korean Ministry of Food and Drug Safety during June and July, and now in Europe. The designation will open doors to several benefits such as market exclusivity for ten years for the drug.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"NIH_begins_a_large_clinical_trial_to_investigate_Immunomodulators_for_COVID-19\"><\/span><strong>NIH begins a large clinical trial to investigate Immunomodulators for COVID-19<\/strong><gwmw style=\"display:none;\"><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US National Institutes of Health (NIH) has initiated an adaptive Phase III clinical trial to test the safety and efficacy of three immunomodulators drugs in hospitalized adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19<\/a> in the United States and Latin America.<\/p>\n\n\n\n<p>Patients suffering from COVID-19 face cytokine storm, which is a result of inflammation due to uncontrolled amounts of proteins released by the immune system in response to virus attack that leads to ARDS, organ failure, and other complications. As per NIH, the study will focus on studying a combination of several treatment regimens with respect to illness severity, recovery speed, mortality, and hospital resource utilization in order to reduce hospital -stays and ventilator use.&nbsp;<\/p>\n\n\n\n<p>The clinical trial, ACTIV-1 Immune Modulators, will enroll approximately 2,100 hospitalized adults with moderate to severe COVID-19. The participants will be randomly assigned to receive one of the immunomodulators or placebo plus remdesivir.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Genesis_Therapeutics_Roche_together_on_the_road_to_AI-driven_drug_discovery\"><\/span><strong>Genesis Therapeutics, Roche together on the road to AI-driven drug discovery<\/strong><gwmw style=\"display:none;\"><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Genentech, a subsidiary of Roche, has teamed up with Genesis Therapeutics, formed as a result of a spin-off from the Stanford University, to bolster the development of an AI-driven drug discovery platform to develop targeted drugs for several diseases.&nbsp;<\/p>\n\n\n\n<p>The collaboration will let Genentech use Genesis\u2019 Dynamic PotentialNet AI platform along with other novel neural network algorithms, while the latter will be eligible to receive upfront payments, milestone payments, and royalties on sales, however, the exact financial terms are not yet released.&nbsp;<\/p>\n\n\n\n<p>It looks like Roche has decided to shoot to the top of the pharmaceutical market, hence is not shying away from doing whatever it takes. Earlier, the company <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cyclerion-nimbus-dyno-rayzebio\/\" target=\"_blank\" rel=\"noreferrer noopener\">collaborated with&nbsp; Dyno Therapeutics<\/a>, acquired Spark Therapeutics, Vaccibody AS to expand its portfolio, and now it\u2019s time for incorporating the technology and AI in its profile.&nbsp;<\/p>\n\n\n\n<p><gwmw style=\"display:none;\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia\u00a0\u00a0 The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older who are unfit for intensive induction chemotherapies.&nbsp; The approval is based on the results of clinical trial Phase lll VIALE-A &amp; [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[59,10830,12513,16718,449,639,524],"industry":[17225],"therapeutic_areas":[17231,17234],"class_list":["post-11054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-myeloid-leukemia-aml","tag-covid-19","tag-covid-19-news","tag-genesis-therapeutics","tag-pancreatic-cancer","tag-pharma-news","tag-roche","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Venclexta approval; PBP1510 ODD; Roche AI collab; P-III COVID-19 Trial<\/title>\n<meta name=\"description\" content=\"Venclexta full approval; PBP1510 Orphan Status for Pancreatic Cancer; Roche\/ Genesis collab; Immunomodulators for COVID-19\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Venclexta approval; PBP1510 ODD; Roche AI collab; P-III COVID-19 Trial\" \/>\n<meta property=\"og:description\" content=\"Venclexta full approval; PBP1510 Orphan Status for Pancreatic Cancer; Roche\/ Genesis collab; Immunomodulators for COVID-19\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-20T09:38:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"481\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Venclexta approval; PBP1510 ODD; Roche AI collab; P-III COVID-19 Trial","description":"Venclexta full approval; PBP1510 Orphan Status for Pancreatic Cancer; Roche\/ Genesis collab; Immunomodulators for COVID-19","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19","og_locale":"en_US","og_type":"article","og_title":"Venclexta approval; PBP1510 ODD; Roche AI collab; P-III COVID-19 Trial","og_description":"Venclexta full approval; PBP1510 Orphan Status for Pancreatic Cancer; Roche\/ Genesis collab; Immunomodulators for COVID-19","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-10-20T09:38:05+00:00","article_modified_time":"2021-07-24T07:28:08+00:00","og_image":[{"width":772,"height":481,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19","name":"Venclexta approval; PBP1510 ODD; Roche AI collab; P-III COVID-19 Trial","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19.png","datePublished":"2020-10-20T09:38:05+00:00","dateModified":"2021-07-24T07:28:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Venclexta full approval; PBP1510 Orphan Status for Pancreatic Cancer; Roche\/ Genesis collab; Immunomodulators for COVID-19","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-prestige-covid-19#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19.png","width":772,"height":481,"caption":"pharma-news-for-roche-prestige-covid-19"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/10\/20165117\/pharma-news-for-roche-prestige-covid-19-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute myeloid Leukemia (AML)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19 News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genesis Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute myeloid Leukemia (AML)<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">COVID-19 News<\/span>","<span class=\"advgb-post-tax-term\">Genesis Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 20, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 20, 2020 3:08 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"pharma-news-for-roche-prestige-covid-19","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11054"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11054\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11061"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11054"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11054"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}